Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) has been assigned a consensus rating of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $72.33.
A number of equities analysts recently weighed in on the company. Wells Fargo & Company initiated coverage on Q32 Bio in a research report on Wednesday, September 11th. They issued an “overweight” rating and a $95.00 price target for the company. Raymond James started coverage on shares of Q32 Bio in a report on Thursday, October 24th. They issued a “strong-buy” rating and a $90.00 target price for the company.
Institutional Inflows and Outflows
Q32 Bio Price Performance
Shares of NASDAQ:QTTB opened at $26.91 on Monday. The company has a market capitalization of $327.76 million, a PE ratio of -1.89 and a beta of -0.32. The company has a debt-to-equity ratio of 0.61, a quick ratio of 6.53 and a current ratio of 6.53. The stock has a fifty day moving average of $41.86 and a 200-day moving average of $34.85. Q32 Bio has a one year low of $9.36 and a one year high of $53.79.
About Q32 Bio
Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.
See Also
- Five stocks we like better than Q32 Bio
- Stock Sentiment Analysis: How it Works
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- Quiet Period Expirations Explained
- 3 Penny Stocks Ready to Break Out in 2025
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Q32 Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q32 Bio and related companies with MarketBeat.com's FREE daily email newsletter.